ARTICLE | Clinical News
Talvesta talotrexin: Suspended Phase I/II enrollment
September 25, 2006 7:00 AM UTC
HNAB suspended the open-label, international Phase II portion of a Phase I/II trial after Talvesta was associated with an incidence of mucositis and myelosuppression in about 8% of the 32 patients enr...